Stock MRUS MERUS N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Merus N.V.

Equities

MRUS

NL0011606264

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
53.33 USD +0.81% Intraday chart for Merus N.V. +0.74% +93.93%
Jun. 04 BMO Capital Raises Price Target on Merus to $91 From $84, Maintains Outperform Rating MT
Jun. 04 Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
GL
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
AQ
Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
GL
Merus Announces Pricing of Upsized Public Offering of Common Shares
GL
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
GL
Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
AQ
Merus N.V. Announces Proposed Public Offering of Common Shares
GL
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
GL
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
AQ
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
GL
Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
AQ
Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
GL
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
GL
Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
AQ
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GL
Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
GL
Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
GL
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
AQ
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRUS Stock
  4. News Merus N.V.
  5. Press Releases